The stock of Navidea Biopharmaceuticals Inc. (AMEX:NAVB) decreased by $0.0 on Tuesday to $0.07, up 2.86 percent. The last five days have seen an average of 1,324,317 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$0.1400. The average number of shares traded over the last 20 days was 2,941,809, while the average volume over the last 50 days totaled 7,500,974.
NAVB stock dropped -34.55% since last month. On 08/07/23, the company’s shares reached a one-month low of $0.0626. The stock touched a high of $0.54 on 02/08/23, after rallying from a low of $0.06 in 52 weeks. The price of NAVB stock has declined by -65.71% or -$0.1400 this year, reaching a new high 4 times. Still, the stock price is down -86.78% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended September 29, Navidea Biopharmaceuticals Inc.’s quick ratio was 0.10, while its current ratio was 0.10, indicating its inability to pay off its debt. Based on annual data, it had gross profit of -$0.12 million and revenue of $66000.0.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. NAVB’s return on assets (ROA) during the last 12 months has been -405.20%. In the meantime, the return on equity (ROE) for the last 12 months was 226.20%.
Earnings Surprise
According to Navidea Biopharmaceuticals Inc.’s quarterly financial report for the quarter that ended September 29. It was predicted that Navidea Biopharmaceuticals Inc.’s quarterly earnings would be -$0.08, but it ended up being -$0.11, beating the consensus by 27.30%. EBITDA was -$2.29 million for the quarter. At the end of Navidea Biopharmaceuticals Inc.’s most recent quarter ended September 29, its liabilities totaled 9.01 million, while its total debt was $1.34 million. Equity owned by shareholders amounts to $99.83 million.
Technical Picture
Here’s a quick look at Navidea Biopharmaceuticals Inc.’s (NAVB) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 36.28%, suggesting the stock is Neutral, with a 116.84% historical volatility rate.
The stochastic %K and %D were 23.13% and 26.53% respectively, while the average true range (ATR) was 0.0088. Based on the 14-day stochastic reading of 18.88%, the RSI (14) reading is 37.36%. On the 9-day MACD Oscillator, the stock is at -0.0001.
Analyst Ratings
In a note to investors, Aegis Capital maintained its a Hold rating on Navidea Biopharmaceuticals Inc. (AMEX: NAVB). However, the firm raised their price target to $2, indicating a possible increase of 97.67% in the stock price. Analysts have assigned Navidea Biopharmaceuticals Inc. (NAVB) an Buy rating. NAVB is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is NAVB’s price target for the next 12 months?
The current consensus forecast for the stock is between $8.00 and $8.00, with a median target price of $8.00. In analyzing these forecasts, the average price target given by analysts for Navidea Biopharmaceuticals Inc. (NAVB) is $8.00.
